These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity. Bates D; Bartholomé E J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):55-60. PubMed ID: 21865211 [TBL] [Abstract][Full Text] [Related]
8. Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis. Muralidharan KK; Steiner D; Amarante D; Ho PR; Mikol D; Elkins J; Subramanyam M; Nestorov I J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):263-275. PubMed ID: 28251386 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study. Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A; Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053 [TBL] [Abstract][Full Text] [Related]
10. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083 [TBL] [Abstract][Full Text] [Related]
11. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Fox RJ; Cree BA; De Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Kaufman M; Montalbán X; Weinstock-Guttman B; Anderson B; Natarajan A; Ticho B; Duda P; Neurology; 2014 Apr; 82(17):1491-8. PubMed ID: 24682966 [TBL] [Abstract][Full Text] [Related]
12. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894 [TBL] [Abstract][Full Text] [Related]
14. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P Neurology; 2014 Jul; 83(1):78-86. PubMed ID: 24898925 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis. Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347 [TBL] [Abstract][Full Text] [Related]